News
News and presentations
Press releases, conference data and company news since our founding in 2019.
All news
-
Press releases
Tacalyx secures €11 million to advance lead TACA-targeting ADC programme toward the clinic
€11 million from the existing syndicate in a first closing of the seed extension. TCX-201 is selected as first clinical candidate, with a CTA filing planned for 2027.
-
Scientific presentations
TCX-201 and TCX-101 data presented at AACR 2026
Two posters at the AACR Annual Meeting 2026 in San Diego: the preclinical profile of first clinical candidate TCX-201 (Poster 5631) and TCX-101 as a trispecific T-cell engager (Poster 5584).
-
Company
April 2026: advisory boards, AACR partnering and two posters
Scientific Advisory Board meeting in Berlin, Clinical Advisory Board meeting and AACR Oncology Industry Partnering Event in San Diego, followed by two posters at AACR 2026.
-
Events
Tacalyx at J.P. Morgan Healthcare week 2026 in San Francisco
CEO Jean Engela meets investors and collaborators in San Francisco from January 12 to 15, 2026.
-
Press releases
Tacalyx appoints Jean Engela as Chief Executive Officer to spearhead next phase of growth
The former CEO of ADC company NBE Therapeutics takes over from co-founder Dr. Peter Sondermann, who continues as Chief Scientific Officer.
-
Scientific presentations
TCX-201 poster at PEGS Europe 2025 in Lisbon
Poster A116 on TCX-201 at the Protein & Antibody Engineering Summit, November 11–13, 2025.
-
Scientific presentations
Talk at PEGS Boston 2025: targeting TACAs with high-affinity antibodies
Dr. Peter Sondermann speaks in the oncology stream of the Protein & Antibody Engineering Summit on May 14, 2025.
-
Scientific presentations
Two TACA antibodies, two modes of action: TCX-201 and TCX-101 at AACR 2025
Poster 1581 in Chicago: TCX-201 as an ADC against a fast-internalizing TACA, TCX-101 as a T-cell engager against a slow-internalizing one.
-
Events
Tacalyx at ESMO 2024 in Barcelona
Prof. Matthias Ocker represents Tacalyx at the ESMO Congress, September 13–17, 2024.
-
Scientific presentations
Two posters at the EORTC-NCI-AACR Symposium 2024
Dr. Wiebke Winkler and Dr. Gustavo Schmidt Moreira present Tacalyx data at ENA 2024 in Barcelona, October 23–25.
-
Company
Co-founder Dr. Oren Moscovitz receives the Max Planck Society's Hermann Neuhaus Prize
The Max Planck Society awards €25,000 to Tacalyx's scientific co-founder for his work on lab-made sugars and alpaca nanobodies against cancer.
-
Press releases
Tacalyx extends seed round to over €14 million
New investor Thuja Capital leads the extension; Evan Castiglia joins the Board of Directors.
-
Scientific presentations
TCX-101 preclinical data presented at AACR 2024
Poster 3125: TCX-101, a novel antibody-drug conjugate targeting a tumor-associated carbohydrate antigen for the treatment of solid tumors.
-
Events
Meet Tacalyx at the AACR Annual Meeting 2024 in San Diego
The team presents TCX-101 and is available for partnering meetings.
-
Press releases
Tacalyx and Leiden University Medical Center join forces to target tumor-specific glycans in colorectal cancer
A €500k Health~Holland grant funds a collaboration with Prof. Manfred Wuhrer's team on the O-glycome of colorectal cancer.
-
Company
Tacalyx appoints Dr. Klaus Schollmeier as Chairman of the Board
A pharma and biotech executive and adviser with more than 30 years of experience in R&D, marketing and general management.
-
Press releases
Tacalyx raises €7 million in seed funding to generate first-in-class anti-TACA antibodies for cancer treatment
The Max Planck spin-out launches with a syndicate co-led by Boehringer Ingelheim Venture Fund and Kurma Partners.
Media inquiries: contact